{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:34:54Z","timestamp":1793885694315,"version":"4.8.0"},"reference-count":85,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant peritoneal mesothelioma (MPM) is an extremely rare malignancy usually confined to the abdominal cavity. With an aggressive natural history, morbidity and mortality are consequences of progressive locoregional effects within the peritoneal cavity. The first reported case was in the early 20th century, however, due to the rare nature of the disease and a large gap in understanding of the clinicopathological effects, the next reported MPM cases were only published half a decade later. Since then, there has been exponential growth in our understanding of the disease, however, there are no prospective data and a paucity of literature regarding management. Traditionally, patients were treated with systemic therapy and the outcomes were very poor, with a median survival of less than one year. However, with the advent of cytoreductive surgery and locoregional chemotherapy, there have been significant improvements in survival. Even more recently, with an improved understanding of the molecular pathogenesis of MPM, there have been reports of improved outcomes with novel therapies. Given the disastrous natural history of MPM, the limited data, and the lack of universal treatment guidelines, an in-depth review of the past, present, and future of MPM is critical to improve treatment regimens and, subsequently, patient outcomes.<\/jats:p>","DOI":"10.3390\/cancers15194704","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T04:15:38Z","timestamp":1695615338000},"page":"4704","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Malignant Peritoneal Mesothelioma: An In-Depth and Up-to-Date Review of Pathogenesis, Diagnosis, Management and Future Directions"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-8186","authenticated-orcid":false,"given":"Josh B.","family":"Karpes","sequence":"first","affiliation":[{"name":"Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, Kogarah, NSW 2217, Australia"},{"name":"St George and Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Shamavonian","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, Kogarah, NSW 2217, Australia"},{"name":"St George and Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-977X","authenticated-orcid":false,"given":"Suzannah","family":"Dewhurst","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, Kogarah, NSW 2217, Australia"},{"name":"St George and Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Cheng","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, Kogarah, NSW 2217, Australia"},{"name":"St George and Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Wijayawardana","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, Kogarah, NSW 2217, Australia"},{"name":"St George and Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, Kogarah, NSW 2217, Australia"},{"name":"St George and Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Morris","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, Kogarah, NSW 2217, Australia"},{"name":"St George and Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: A systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignant peritoneal mesothelioma: A review","volume":"7","author":"Broeckx","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/1097-0142(196001\/02)13:1<127::AID-CNCR2820130124>3.0.CO;2-6","article-title":"Malignant peritoneal mesotheliomas: A clinicopathological analysis of 12 fatal cases","volume":"13","author":"Winslow","year":"1960","journal-title":"Cancer"},{"key":"ref_4","first-page":"311","article-title":"Malignant peritoneal mesothelioma: Review of 25 patients","volume":"75","author":"Brenner","year":"1981","journal-title":"Am. J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0399-8320(07)73964-7","article-title":"Malignant peritoneal mesothelioma: Treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy","volume":"31","author":"Elias","year":"2007","journal-title":"Gastroenterol. Clin. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: Prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/annonc\/mdl060","article-title":"Current treatment options and biology of peritoneal mesothelioma: Meeting summary of the first NIH peritoneal mesothelioma conference","volume":"17","author":"Hassan","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jso.21055","article-title":"Consensus statement on peritoneal mesothelioma","volume":"98","author":"Deraco","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1200\/JOP.2016.011908","article-title":"Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy","volume":"12","author":"Sugarbaker","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.21037\/tlcr.2018.08.03","article-title":"Update on the management of malignant peritoneal mesothelioma","volume":"7","author":"Sugarbaker","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","article-title":"Current trends in the management of malignant peritoneal mesothelioma","volume":"21","author":"Miura","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ullah, A., Waheed, A., Khan, J., Mishra, A., Tareen, B., Nama, N., Karki, N.R., Panezai, M.S., Zarate, L.V., and White, J. (2022). Incidence, Survival Analysis and Future Perspective of Primary Peritoneal Mesothelioma (PPM): A Population-Based Study from SEER Database. Cancers, 14.","DOI":"10.3390\/cancers14040942"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/bjs.7263","article-title":"Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma","volume":"98","author":"Chua","year":"2011","journal-title":"Br. J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1245\/s10434-017-6293-5","article-title":"Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry","volume":"25","author":"Votanopoulos","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","first-page":"32","article-title":"Peritoneal mesothelioma: A review","volume":"9","author":"Bridda","year":"2007","journal-title":"Medscape Gen. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Calthorpe, L., Romero-Hernandez, F., Miller, P., Conroy, P.C., Hirose, K., Kim, A., Kirkwood, K., Nakakura, E., Corvera, C., and Maker, A.V. (2022). Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States. Cancers, 15.","DOI":"10.3390\/cancers15010229"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/dmr-22-19","article-title":"Malignant peritoneal mesothelioma literature review: Past, present, and future","volume":"5","author":"Gregory","year":"2022","journal-title":"Dig. Med. Res."},{"key":"ref_20","first-page":"673","article-title":"[Malignant peritoneal mesothelioma tumours. Evolution, treatment, prognosis]","volume":"111","author":"Scripcariu","year":"2007","journal-title":"Rev. Med. -Chir. A Soc. De Medici Si Nat. Din Iasi"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.21037\/tlcr.2019.12.15","article-title":"Peritoneal mesothelioma","volume":"9","author":"Greenbaum","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004836-200109000-00018","article-title":"Recurrent peritoneal mesothelioma with long-delayed recurrence","volume":"33","author":"Tandar","year":"2001","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/15513819209023314","article-title":"Mesothelial and related neoplasms in children and adolescents: A clinicopathologic and immunohistochemical analysis of eight cases","volume":"12","author":"Coffin","year":"1992","journal-title":"Pediatr. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.21037\/jgo.2017.08.01","article-title":"Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: A review","volume":"8","author":"Mehta","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/PAP.0000000000000387","article-title":"Peritoneal Mesothelioma-An Update","volume":"30","author":"Malpica","year":"2023","journal-title":"Adv. Anat. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant Mesothelioma and Its Non-Asbestos Causes","volume":"142","author":"Attanoos","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00384-014-2029-1","article-title":"Advances in malignant peritoneal mesothelioma","volume":"30","author":"Cao","year":"2015","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s00261-015-0429-5","article-title":"The subperitoneal space and peritoneal cavity: Basic concepts","volume":"40","author":"Pannu","year":"2015","journal-title":"Abdom. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Alyami","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","article-title":"The histophysiology and pathophysiology of the peritoneum","volume":"49","author":"Nieuwland","year":"2017","journal-title":"Tissue Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options","volume":"40","author":"Tsao","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"823839","DOI":"10.3389\/fonc.2022.823839","article-title":"Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights","volume":"12","author":"Fortarezza","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41379-020-0588-y","article-title":"Molecular characterization of diffuse malignant peritoneal mesothelioma","volume":"33","author":"Hung","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jss.2022.04.005","article-title":"Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study","volume":"277","author":"Gazivoda","year":"2022","journal-title":"J. Surg. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41416-020-01130-x","article-title":"Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy","volume":"124","author":"White","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.2147\/CMAR.S170300","article-title":"Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: Patient selection and special considerations","volume":"11","author":"Enomoto","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4149\/neo_2014_053","article-title":"Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma","volume":"61","author":"Kaya","year":"2014","journal-title":"Neoplasma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2214\/AJR.07.3628","article-title":"Peritoneal mesotheliomas: Clinicopathologic features, CT findings, and differential diagnosis","volume":"191","author":"Park","year":"2008","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cncr.20836","article-title":"Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy","volume":"103","author":"Yan","year":"2005","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s002470050732","article-title":"Malignant peritoneal mesothelioma in two pediatric patients: MR imaging findings","volume":"30","author":"Haliloglu","year":"2000","journal-title":"Pediatr. Radiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1245\/s10434-014-4041-7","article-title":"Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures","volume":"22","author":"Low","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MNM.0000000000000649","article-title":"The role of 18F-FDG-PET\/ceCT in peritoneal mesothelioma","volume":"38","author":"Dubreuil","year":"2017","journal-title":"Nucl. Med. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1245\/s10434-006-9192-8","article-title":"Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion","volume":"14","author":"Baratti","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ejso.2009.04.007","article-title":"Circulating CA125 and diffuse malignant peritoneal mesothelioma","volume":"35","author":"Baratti","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejso.2018.02.010","article-title":"Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study","volume":"44","author":"Bruno","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/bjs.8908","article-title":"Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis","volume":"100","author":"Iversen","year":"2013","journal-title":"Br. J. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1245\/s10434-015-4958-5","article-title":"Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery","volume":"23","author":"Marmor","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s13193-015-0486-9","article-title":"Diagnostic Laparoscopy in the Pre-operative Assessment of Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancies","volume":"7","author":"Seshadri","year":"2016","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_54","first-page":"187","article-title":"Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma","volume":"23","author":"Laterza","year":"2009","journal-title":"Vivo"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5792\/ksrr.2013.25.2.43","article-title":"Thromboprophylaxis for deep vein thrombosis and pulmonary embolism after total joint arthroplasty in a low incidence population","volume":"25","author":"Kim","year":"2013","journal-title":"Knee Surg. Relat. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.25640","article-title":"A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database","volume":"117","author":"Yan","year":"2011","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ejso.2006.03.002","article-title":"Quantitative prognostic indices in peritoneal carcinomatosis","volume":"32","author":"Gilly","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41379-020-00688-4","article-title":"Malignant peritoneal mesothelioma: Prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases","volume":"34","author":"Chapel","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jso.10081","article-title":"Malignant transformation of \u201cbenign\u201d cystic mesothelioma of the peritoneum","volume":"79","author":"Yan","year":"2002","journal-title":"J. Surg. Oncol."},{"key":"ref_60","first-page":"659","article-title":"Malignant peritoneal mesothelioma: Clinical aspects, and therapeutic perspectives","volume":"31","author":"Boussios","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"839","DOI":"10.21873\/anticanres.13183","article-title":"Malignant Peritoneal Mesothelioma: Treatment Options and Survival","volume":"39","author":"Salo","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","article-title":"Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study","volume":"65","author":"Kepenekian","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12032-018-1125-4","article-title":"The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking","volume":"35","author":"Naffouje","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.6004\/jnccn.2012.0008","article-title":"Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma","volume":"10","author":"Turner","year":"2012","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1245\/s10434-017-5834-2","article-title":"Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy","volume":"24","author":"Li","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1245\/s10434-012-2237-2","article-title":"Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: A controlled study","volume":"19","author":"Baratti","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1245\/s10434-018-6631-2","article-title":"Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study","volume":"25","author":"Malgras","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","article-title":"Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival","volume":"43","author":"Sugarbaker","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jso.27301","article-title":"Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes","volume":"128","author":"Deban","year":"2023","journal-title":"J. Surg. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1245\/s10434-014-3977-y","article-title":"Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome","volume":"22","author":"Ihemelandu","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/SLA.0b013e3182436c28","article-title":"Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies","volume":"255","author":"Kusamura","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/bjs.9674","article-title":"Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"101","author":"Kusamura","year":"2014","journal-title":"Br. J. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jso.21177","article-title":"Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian experience","volume":"99","author":"Chua","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.21873\/anticanres.15776","article-title":"Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival from an Australian Centre","volume":"42","author":"Shamavonian","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-006-9182-x","article-title":"A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"14","author":"Yan","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/onco.13714","article-title":"A novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20: A case report and literature review","volume":"26","author":"Miyagawa","year":"2021","journal-title":"Oncologist"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"vi137","DOI":"10.1093\/annonc\/mdz343.089","article-title":"TACKLE: A phase II study of alectinib in patients with unresectable rare cancer harboring ALK alterations (NCCH1712)","volume":"30","author":"Narita","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/annonc\/mdv101","article-title":"Searching for targets for the systemic therapy of mesothelioma","volume":"26","author":"Stahel","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib Plus Pemetrexed\/Cisplatin in Patients with Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study","volume":"3","author":"Morra","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e237721","DOI":"10.1136\/bcr-2020-237721","article-title":"Nivolumab for malignant peritoneal mesothelioma","volume":"13","author":"Tanaka","year":"2020","journal-title":"BMJ Case Rep. CP"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3892\/mco.2023.2627","article-title":"Immunotherapy in malignant peritoneal mesothelioma (review)","volume":"18","author":"Alaklabi","year":"2023","journal-title":"Mol. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4704\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:57:19Z","timestamp":1760129839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":85,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15194704"],"URL":"https:\/\/doi.org\/10.3390\/cancers15194704","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]}}}